1. Clinical & Scientific Overview
Sertraline Hydrochloride (TIP-MED-000205, Reference Code [11.1]) is classified under
CNS & Psychiatric Medicines (Ch 11) as a Selective Serotonin Reuptake Inhibitor (SSRI Antidepressant & Anxiolytic).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.1], p. 140): Zoloft (Pfizer), Serlift (Sun Pharma), Daxid (Pfizer), Sertima (Intas), Serta (Unichem) — Strengths & Dosage Forms: Oral Film-Coated Scored Tablets: 25 mg, 50 mg, 100 mg
Oral Film-Coated Scored Tablets: 25 mg, 50 mg, 100 mg
3. Mechanism of Action & Pharmacodynamics
Selective Serotonin Reuptake Inhibitor (SSRI Antidepressant & Anxiolytic) acting on target receptor/enzyme pathways in CNS & Psychiatric Medicines (Ch 11): clinical efficacy is mediated via Selective Serotonin Reuptake Inhibitor (SSRI Antidepressant & Anxiolytic) for Major depressive disorder (preferred first-line SSRI in patients with Ischaemic Heart Disease / post-Myocardial Infarction based on SADHART trial safety!); generalised anxiety disorder, panic disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and social anxiety disorder..
4. Therapeutic Indications & Evidence-Supported Uses
- Major depressive disorder (preferred first-line SSRI in patients with Ischaemic Heart Disease / post-Myocardial Infarction based on SADHART trial safety!)
- generalised anxiety disorder, panic disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and social anxiety disorder
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Initially 25 mg to 50 mg once daily; may increase by 25–50 mg at intervals of ≥1–2 weeks to usual maintenance 50 mg–150 mg once daily (Maximum 200 mg/day). In elderly: initiate at 25 mg once daily. Follow psychiatrist/physician prescription.
Administration & Meal Timing: Take WITH or immediately AFTER breakfast (food increases peak plasma concentration Cmax by ~25% and significantly reduces initial serotonergic nausea and loose stools). | Once daily in the morning after breakfast (or evening if it causes mild drowsiness in a specific patient).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Excreted minimally unchanged in urine; no dose adjustment required across any stage of CKD. Hepatic: Extensively metabolised by the liver—in mild cirrhosis, reduce dose by 50% (start 25 mg OD); avoid in severe decompensated liver disease.
Renal: Excreted minimally unchanged in urine; no dose adjustment required across any stage of CKD. Hepatic: Extensively metabolised by the liver—in mild cirrhosis, reduce dose by 50% (start 25 mg OD); avoid in severe decompensated liver disease.
Renal: Excreted minimally unchanged in urine; no dose adjustment required across any stage of CKD. Hepatic: Extensively metabolised by the liver—in mild cirrhosis, reduce dose by 50% (start 25 mg OD); avoid in severe decompensated liver disease.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated with Monoamine Oxidase Inhibitors (MAOIs—require a 14-day washout), linezolid, and pimozide. Caution in history of bipolar mania (can trigger manic switch), epilepsy, bleeding disorders/anticoagulant use, angle-closure glaucoma, and elderly patients prone to hyponatraemia.
Key Clinical Precautions: Renal: Excreted minimally unchanged in urine; no dose adjustment required across any stage of CKD. Hepatic: Extensively metabolised by the liver—in mild cirrhosis, reduce dose by 50% (start 25 mg OD); avoid in severe decompensated liver disease.
8. Adverse Effects Profile
- Transient nausea, loose stools/diarrhoea (most GI-active SSRI during Week 1–2—improves with food and time), insomnia or mild somnolence, headache, dry mouth, fine tremor, increased sweating, sexual dysfunction (delayed ejaculation/anorgasmia).
- Hyponatraemia due to SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion—occurs mostly within the first 2 to 4 weeks in elderly patients >65 years, especially if also taking a thiazide diuretic [Telma-H/CT]!: presents with lethargy, confusion, unsteadiness, and seizures), Upper GI Bleeding (SSRIs deplete platelet serotonin required for platelet aggregation—risk triples when combined with Aspirin, Clopidogrel, NSAIDs, or Anticoagulants!), Serotonin Syndrome, early activation/suicidal ideation in young adults (<25 years).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Antiplatelets (Aspirin, Clopidogrel), Anticoagulants (Warfarin, Apixaban, Rivaroxaban), and NSAIDs: Significantly increases risk of gastrointestinal haemorrhage—co-prescribe a PPI (Pantoprazole)! 2
- Tramadol (Ultracet), Linezolid, Triptans, Lithium, and St
- John's Wort: High risk of life-threatening Serotonin Syndrome (clonus, agitation, hyperthermia, tremor)! 3
- Thiazide Diuretics (HCTZ, Chlorthalidone): Synergistic risk of severe SIADH Hyponatraemia in the elderly! (Note: Sertraline has mild CYP2D6 inhibition only at high doses ≥150 mg, and minimal QTc effect compared to citalopram/escitalopram)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Manage the '2-Week Lag Gap': Explain to the patient and family: 'In the first 7 to 10 days of starting Serlift/Daxid, you may feel slight stomach queasiness or restlessness before your mood starts lifting around Week 2 to 4—taking it right after breakfast helps, and please do not stop the tablet in the first week!' Also warn never to stop suddenly once feeling better, as sudden stopping causes dizziness and electric-shock ('brain-zap') sensations.
- Meal & Clock Timing Instruction: Take WITH or immediately AFTER breakfast (food increases peak plasma concentration Cmax by ~25% and significantly reduces initial serotonergic nausea and loose stools). (Once daily in the morning after breakfast (or evening if it causes mild drowsiness in a specific patient).)
- Missed Dose Protocol: Take as soon as remembered on the same day; skip if close to next morning's dose. Never double.
- Geriatric Dispensing Pearl: First-choice antidepressant in elderly CGHS cardiac patients (post-MI, angina, heart failure) due to its cardiovascular safety and low CYP450 interaction burden; always check Serum Sodium at Week 2–3 and ensure Pantoprazole cover if the patient takes Ecosprin/Clopidogrel.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Scored Tablets: 25 mg, 50 mg, 100 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 11 [11.1] (p. 140)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.24] Aripiprazole (Dopamine D2 Partial Agonist Antipsychotic) — Third-Generation Quinolinone Antipsychotic (Dopamine D2 / Seroton
- [11.25] Clozapine (Treatment-Resistant Schizophrenia — ANC Protocol) — Atypical Dibenzodiazepine Antipsychotic for Treatment-Resistant S
- [11.26] Lithium Carbonate (Mood Stabiliser — Narrow Therapeutic Index) — Monovalent Cation Mood Stabiliser (Inositol Monophosphatase & GSK
- [11.5]-CMP129 Etizolam IP — Short-to-Intermediate Acting Triazolobenzodiazepine (GABA-A Recep
